Skip to content

Collect Digital Data

Opportunity

Participants expect a simple and convenient experience participating on clinical trials. To accomplish this goal, sponsors should consider the type, design and delivery of device (e.g., personal device,  provided by study, etc.) for participants to achieve accessibility, flexibility, convenience and maintain privacy. 

Considerations to Help Action the Opportunity

  • Understand if the clinical trial design supports the applications of digital patient solutions
  • Understand the needs and preferences of the participants taking part in the trial
    • Does the population have access to devices and data plans, or would they need these to be provisioned?
    • What devices would participants already have that could be used for clinical trials (e.g., wearables / sensors, glucometers, weighing scales, phones / tablets, etc.​)?
    • Understand impact on health equity (i.e., geographic, socioeconomic barriers) when implementing digital solutions 
  • Partner with sites to gain their input on the impact of multiple services, training, and technology implementation
  • Understand how the device may impact data integrity, regulatory landscape, site implementation and overall costs  
  • Define how technology is designed, communicated and delivered for / to participants
  • Define backup options (e.g., when a participant is unable to connect to device)

Value and Potential Benefits

  • Increases access and ease of participation for participants on clinical trials by potentially reducing the number of site visits
  • Allows for more robust datasets with improved data compliance and quality by enabling direct entry and near real-time review of data

Related Blog Posts

Enough, already: the problem with clinical trial data collection

The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are…

2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs

In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…